Under the terms of the agreement, BD’s BD Biosciences Custom Technology Team will perform sample analysis on Amarantus’ LymPro Test for Alzheimer’s disease.
Amarantus president and CEO Gerald Commissiong said that the LymPro Test is potentially the first available blood test for Alzheimer’s disease.
"With this agreement, we expect to have initial data available in the third quarter of 2013, and now have the capabilities required to place LymPro on a path for commercialization in 2014," Commissiong added.
Both the companies aim to verify the analytical performance characteristics of LymPro necessary to achieve reproducibility of the assay.
Amarantus expects to execute multiple clinical studies and begin worldwide sales of LymPro as the first diagnostic blood test for Alzheimer’s disease.
The financial terms of the service agreement were not disclosed.